NEURELIS ANNOUNCES RAPID AND BROAD PAYER COVERAGE OF THE COMPANY’S FLAGSHIP PRODUCT, VALTOCO® (DIAZEPAM NASAL SPRAY)
— More than 176 million lives in the U.S. now covered by payers/managed care/insurance plans within months of FDA approval of VALTOCO, the first and only nasal spray treatment of seizure clusters in patients 6 years of age and older — Neurelis’ patient assistance program supports eligible patients who have no health insurance — Co-pay […]